Clinical trials
Peripheral Blood Stem Cell Transplantation clinical trials
Below are recruiting peripheral blood stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 173 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03810196Recruiting
Stem cell addback after transplant to treat viral or fungal infection
This study tests a stem cell “addback” treatment after a specific type of transplant (with certain immune cells removed). It may help the body recover faster and fight serious viral or fungal infections in children and teens.
Philadelphia, PennsylvaniaAges Up to 25 years - NCT03520647RecruitingPhase 2
Haplo transplant for severe bone marrow failure using donor cells
This trial tests a stem cell transplant from a closely matched but not fully matched family donor (haploidentical), with chemotherapy after the transplant to help prevent graft-versus-host disease (GVHD). It may help people with severe aplastic anemia, certain MDS after transformation, or PNH when other treatments have not worked or are not available.
Bethesda, MarylandAges 4–75 - NCT03707262RecruitingPhase 1/Phase 2
Brother or sister donor transplant using kidney and stem cells
This study tests a combined approach for kidney transplant patients: standard living-donor kidney transplant plus an added “stem cell” component taken from the same sibling donor. It aims to improve transplant outcomes by trying to better control the immune response and reduce complications.
Los Angeles, CaliforniaAges 18 years+ - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03378102RecruitingEarly Phase 1
AdV-targeted T cells for adenovirus after bone marrow transplant
This trial tests a custom immune cell treatment (T cells made to recognize adenovirus) for people whose adenovirus infection is not improving or who cannot tolerate standard antiviral medicines after a bone marrow transplant. It aims to help your body control the virus and prevent organ complications.
Cleveland, OhioAges 3 months+ - NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT01666080Recruiting
Second bone marrow transplant with gentler chemotherapy
This trial studies a “reduced intensity” second transplant using donated blood-forming cells, for people whose first transplant did not fully and reliably restart blood production. It aims to improve donor blood cell growth while using a less harsh conditioning approach.
Minneapolis, MinnesotaAges Up to 55 years - NCT00001405Recruiting
Blood Cell Collection Study for Immune and Blood Disorders
This study collects blood cells and bone marrow from people with immune system or blood disorders, and from healthy volunteers. Researchers will study these cells and may convert them into special stem cells (iPS cells) to better understand diseases and develop treatments.
Bethesda, MarylandAges 18–70 - NCT07389616RecruitingPhase 2/Phase 3
Preventing lymphoma return after transplant
This trial tests a combination of two drugs (cidabenamine and azacitidine) to help prevent peripheral T-cell lymphoma from coming back after a donor stem cell transplant. It is for patients who are at high risk of progression and have already had a transplant.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07269041RecruitingPhase 1/Phase 2
Immune tolerance after liver transplant
This trial tests a way to help your body accept your liver transplant without needing lifelong anti-rejection drugs. It uses your living donor's stem cells to train your immune system to not attack the new liver.
Los Angeles, CaliforniaAges 18 years+ - NCT05711667RecruitingPhase 3
Letermovir to prevent CMV after stem cell transplant in kids
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
Birmingham, AlabamaAges 2–18 - NCT03665675RecruitingEarly Phase 1
Immune cell treatment to control CMV or adenovirus after transplant
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
Columbus, OhioAges 1–85 - NCT02859402RecruitingPhase 2
Donor stem cell transplant for relapsed T or NK lymphoma
This Phase 2 study tests an allogeneic (donor) stem cell transplant for people with T-cell or NK-cell lymphomas that came back or did not respond to prior treatment. It may help by giving you new, healthy immune cells that can attack the cancer.
BusanAges 19–65 - NCT06581081Recruiting
CAR-T therapy with or without stem cell transplant for B-cell leukemia
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
Beijing, Beijing MunicipalityAges 12–65 - NCT05561387RecruitingPhase 3
Drug combinations for newly diagnosed myeloma without transplant
This study compares different combinations of medicines for people newly diagnosed with multiple myeloma who cannot safely get a stem cell transplant. It aims to find which drug plan works best and is tolerable for people with “frail” or “intermediate fit” health.
Anchorage, AlaskaAges Any age - NCT07106710RecruitingPhase 2
Stem cell transplant plus two targeted therapies for ultra-high-risk myeloma
This trial tests a stem cell transplant followed by two targeted therapies — a BCMA CAR-T and a GPRC5D/CD3 bispecific antibody — to treat newly diagnosed multiple myeloma that has ultra-high-risk features. The goal is to see if this combination can better control the disease.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06608732RecruitingPhase 2
CAR-T therapy plus stem cell transplant for B-cell ALL with MRD
This trial tests a combination of a CAR-T cell therapy (Inaticabtagene Autoleucel) followed by your own stem cells being transplanted back into you. It is for teenagers and adults who have B-cell acute lymphoblastic leukemia (ALL) that is in first complete remission but still has tiny amounts of cancer cells (called MRD) that can be detected by sensitive tests.
Tianjin, Tianjin MunicipalityAges 16–70 - NCT06641648RecruitingPhase 1
Donor NK cells with low-dose IL-2 for AML relapse after stem cell transplant
This trial tests a new treatment for patients whose acute myeloid leukemia (AML) has come back after a stem cell transplant. It uses immune cells from the original donor, combined with a low dose of a protein called IL-2, to try to fight the leukemia without causing severe side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04491370RecruitingPhase 1/Phase 2
Stem cell transplant then polatuzumab for certain lymphomas
This trial tests whether doing your own stem cell transplant, followed by polatuzumab, can improve outcomes in people with specific B-cell non-Hodgkin or Hodgkin lymphomas that did not fully respond or has come back. It aims to add a targeted medicine after transplant to help control the lymphoma.
Valhalla, New YorkAges 12–70 - NCT04691622RecruitingPhase 1
Treat chronic norovirus using donor immune cells
This Phase 1 study tests whether giving immune cells made from a donor can help children and adults with long-lasting (chronic) norovirus infection. It’s aimed at people whose immune system is weakened after a stem cell transplant, solid organ transplant, or due to primary immune problems.
Washington D.C., District of ColumbiaAges 3 months–80 years - NCT05477589RecruitingPhase 3
Conditioning plan for kids with AML before stem cell transplant
This Phase 3 trial studies the best “conditioning” chemotherapy plan before an allogeneic stem cell transplant for children with AML. It may help improve outcomes by testing an approach for kids who are ready for transplant after relapse or specific high-risk features.
BrusselsAges Up to 18 years - NCT06926595RecruitingPhase 2
Stem cell transplant with low-dose chemo for graft-versus-host disease prevention
This trial tests a stem cell transplant using a reduced-intensity chemotherapy regimen and a low dose of a drug called cyclophosphamide after the transplant to help prevent graft-versus-host disease (GVHD), a common complication where donor cells attack the recipient's body. It is for people with certain blood cancers or bone marrow disorders who have a suitable donor.
Hershey, PennsylvaniaAges 18 years+ - NCT06918002RecruitingPhase 3
Comparing elranatamab with standard care for newly diagnosed multiple myeloma
This trial tests if adding the immunotherapy drug elranatamab (with or without lenalidomide) after initial treatment works better than the usual care for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant.
BrusselsAges 18–69 - NCT05797272Recruiting
In-utero stem cell treatment for Bart’s hydrops
This trial studies whether giving hematopoietic (blood-forming) stem cells while the baby is still in the womb can treat fetuses with Bart’s hydrops fetalis syndrome. It aims to improve outcomes after prenatal intervention in carefully selected pregnancies.
ShatinAges 18 years+
Hear when a new Peripheral Blood Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for peripheral blood stem cell transplantation?
- Yes. Clin2 currently lists 173 recruiting peripheral blood stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a peripheral blood stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a peripheral blood stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation
- Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Haploidentical Hematopoietic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.